The majority of patients with chronic‐phase (CP) chronic myeloid leukemia (CML) who are
treated with Bcr‐Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …

The bcr-abl chimeric messenger RNA is frequently detected in chronic myeloid leukemia
(CML) patients after bone marrow transplantation. It was previously reported that the relapse …

In chronic myelogenous leukemia (CML), amplification of a segment of bcr-abl messenger
RNA (mRNA) by polymerase chain reaction (PCR) can be used to detect minimal residual …

Molecular monitoring for patients with chronic myeloid leukaemia (CML) has become an
important practice in the era of imatinib therapy. For successful widespread introduction into …

Bone marrow BCR‐ABL transcript levels were monitored serially by real‐time quantitative
PCR in 46 imatinib‐treated chronic myeloid leukemia patients after achieving complete …

Background and objective: Accurate quantification of BCR-ABL mRNA is of critical
importance for managing chronic myeloid leukemia (CML) patients receiving Imatinib …

We have used a new single‐step real‐time reverse transcription polymerase chain reaction
(RT‐PCR) method to quantify BCR‐ABL transcripts, thereby estimating the relapse stage in …

The polymerase chain reaction (PCR) has become a standard method for highly sensitive
detection of the bcr/abl rearrangement in patients with chronic myelogenous leukemia …

We describe the methodology and application of the polymerase chain reaction to detect
BCR-ABL mRNA as a marker for CML cells. The technique is highly sensitive enabling the …

Detection of BCR-ABL transcripts in chronic myeloid leukaemia (CML) is used to confirm the
diagnosis and to monitor residual disease. Quantitative techniques are required to predict …